NASDAQ:PULM Pulmatrix Q3 2025 Earnings Report $1.61 -0.06 (-3.59%) Closing price 09/25/2026 03:59 PM EasternExtended Trading$1.62 +0.01 (+0.62%) As of 09/25/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Pulmatrix EPS ResultsActual EPS-$0.24Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/APulmatrix Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APulmatrix Announcement DetailsQuarterQ3 2025Date10/16/2025TimeBefore Market OpensConference Call DateThursday, October 16, 2025Conference Call Time7:00AM ETUpcoming EarningsPulmatrix's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 9, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings Documents Pulmatrix Earnings HeadlinesAnalyzing Urogen Pharma (NASDAQ:URGN) & Pulmatrix (NASDAQ:PULM)September 27 at 9:14 AM | americanbankingnews.comPulmatrix, Inc. (NASDAQ:PULM) Stock Short Interest Rises 174.2%September 27 at 6:52 AM | americanbankingnews.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.September 27 at 1:00 AM | Altimetry (Ad)Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting MitochondriaSeptember 22, 2026 | globenewswire.comPulmatrix Inc.: Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on MergerAugust 13, 2026 | finanznachrichten.dePulmatrix Announces Second Quarter 2026 Financial Results and Progress on MergerAugust 13, 2026 | prnewswire.comSee More Pulmatrix Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pulmatrix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pulmatrix and other key companies, straight to your email. Email Address About PulmatrixPulmatrix (NASDAQ:PULM) is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for respiratory and other serious diseases. The company’s approach is designed to deliver medicines directly to the lungs, potentially improving local drug exposure while limiting systemic side effects. Pulmatrix’s technology platform, iSPERSE, is an engineered dry-powder formulation designed to enable the inhalation of a broad range of drug compounds. The platform has been used in the development of products including PUR1900, an inhaled formulation of itraconazole being investigated for respiratory fungal infections such as allergic bronchopulmonary aspergillosis, and other investigational therapies targeting pulmonary and related conditions. Based in Lexington, Massachusetts, Pulmatrix has historically focused on advancing inhaled treatments through preclinical and clinical development, while pursuing potential partnerships and commercialization opportunities. Its programs and corporate priorities may change as clinical data, regulatory decisions and financing conditions evolve.View Pulmatrix ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/252 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindCostco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem5 Scary-Good Stocks With Strong October Catalysts and Breakout PotentialDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
